Portal de recerca
ESTUDIO PROSPECTIVO OBSERVACIONAL, SOBRE LA EFICACIA DE NUEVOS FARMACOS ANTIEPILEPTICOS COMO PRIMERA BITERAPIA EN LA PRACTICA MEDICA HABITUAL. ESTUDIO LICEO.
Dades bàsiques
- Protocol:
- PFI-PRE-2006-01
- EURDRACT:
- NO PROCEDE
- NCT:
- Centre:
- Any inici:
- Any de finalització:
Documents
- No hi ha documents
Participants
Finançadors - Promotors
Resultats de l'Assaig Clínic
12-Month Effectiveness and Tolerability of Brivaracetam in the Real-World: The International EXPERIENCE Pooled Analysis
Villanueva, Vicente; (...); Steinhoff, Bernhard J.
Meeting Abstract. 10.1212/WNL.0000000000201896. 2023
A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA).
Hahn, Cecil D.; (...); Dlugos, Dennis
Article. 10.1111/epi.17367. 2022
A systematic review of behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate in real-world studies
Steinhoff, Bernhard J.; (...); Villanueva, Vicente
Meeting Abstract. 2021
Academic and employment insertion as a factor related to quality of life in patients with drug-resistant temporal lobe epilepsy.
Catalán-Aguilar J; (...); Cano-López I
Article. 10.33588/rn.7407.2020684. 2022
Anti-GAD65-related epilepsy and its clinical spectrum
Marin Gracia, M.; (...); Villanueva, V.
Meeting Abstract. 2024
Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review.
Steinhoff, Bernhard J; (...); Villanueva, Vicente
Review. 10.1016/j.yebeh.2021.107939. 2021
BRIVA-ONE study: 12-month outcomes of brivaracetam monotherapy in clinical practice
Villanueva, V.; (...); Sansa, G.
Meeting Abstract. 2024
BRIVA-ONE study: 12-month outcomes of brivaracetam monotherapy in clinical practice.
Villanueva V; (...); Serratosa JM
Article. 10.1002/epi4.13078. 2024
Brivaracetam effectiveness and tolerability in older and younger adults with epilepsy: EXPERIENCE, a pooled analysis of international data from retrospective studies.
Faught, Edward; (...); Villanueva, Vicente
Article. 10.1016/j.yebeh.2024.109922. 2024
Candidate Selection for Implantation: Noninvasive Predictors of Seizure Onset Zone Focality and Surgical Outcome in People with Drug-Resistant Epilepsy Evaluated by Intracranial Video-EEG Monitoring-A Retrospective Cohort Study
Jannone-Pedro, Nicolas; (...); Villanueva, Vicente
Article. 10.1155/2023/3455061. 2023
Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain
Garcia-Penas, JJ; (...); Villanueva-Haba, V
Article. 10.33588/rn.73S01.2021250. 2021
Cardiovascular response to stress in patients with drug-resistant epilepsy: preliminary data
Lozano-Garcia, A; (...); Cano-Lopez, I
Article. 10.6018/analesps.483021. 2021
CLINICAL AND ECONOMIC CONSEQUENCES OF EPILEPSY TREATMENT ACROSS INCREMENTAL TREATMENT LINES IN SPAIN: A REAL LIFE DATABASE ANALYSIS
Toledano, R.; (...); Hernandez, I
Meeting Abstract. 2023
Clinical and economic implications of epilepsy management across treatment lines in Spain: a real-life database analysis.
Toledano R; (...); Pérez-Domper P
Article. 10.1007/s00415-023-11958-x. 2023
Clinical characteristics of patients achieving seizure freedom in a phase 2 trial evaluating adjunctive cenobamate
Brandt, C.; (...); Steinhoff, B.
Meeting Abstract. 2022
Clinical utility of Epitrack for differentiating profiles and patterns of post-surgical change in memory and quality of life in patients with drug-resistant epilepsy.
Lozano-García A; (...); González-Bono E
Article. 10.1080/23279095.2022.2036990. 2022
Cognitive phenotypes in patients with drug-resistant temporal lobe epilepsy: Relationships with cortisol and affectivity.
Cano-Lopez, Irene; (...); Gonzalez-Bono, Esperanza
Article. 10.1080/13854046.2024.2375605. 2024
Design of two parallel randomized, double-blind, placebo-controlled phase 3 studies to evaluate the safety and efficacy of XEN1101 as adjunctive therapy in the treatment of focal onset epilepsy
Perucca, E.; (...); Beatch, G. N.
Meeting Abstract. 2023
Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain.
Angel Calleja, Miguel; (...); Gil, Alicia
Article. 10.1080/14737167.2022.2107507. 2022
Development and validation of the Epilepsy Perceived Stress Inventory for Adults (EPSI-A): A pilot study
Catalan-Aguilar, Judit; (...); Gonzalez-Bono, Esperanza
Article. 10.1016/j.yebeh.2024.110142. 2024
Drug load and memory during intracarotid amobarbital procedure in epilepsy
Lozano-García A; (...); Villanueva V
Editorial Material. 10.1111/ane.13491. 2021
Effect of concomitant medications on adverse event frequency, severity, and resolution in a cenobamate open-label trial
Steinhoff, B.; (...); Villanueva, V.
Meeting Abstract. 2024
Effectiveness and safety of perampanel in elderly epilepsy patients (aged >= 65 years) treated in everyday clinical practice
McMurray, Rob; (...); Villanueva, Vicente
Meeting Abstract. 2021
Effectiveness and Tolerability of 12-Month Brivaracetam in the Real World: EXPERIENCE, an International Pooled Analysis of Individual Patient Records.
Villanueva V; (...); Steinhoff BJ
Article. 10.1007/s40263-023-01033-4. 2023
Effectiveness and tolerability of brivaracetam in patients with epilepsy stratified by comorbidities and etiology in the real world: 12-month subgroup data from the international EXPERIENCE pooled analysis.
Szaflarski, Jerzy P; (...); Villanueva, Vicente
Article. 10.1007/s00415-024-12253-z. 2024
Effectiveness and Tolerability of Perampanel in Epilepsy Patients Treated in Routine Clinical Practice: a Global Pooled Analysis Study
D'Souza, Wendyl; (...); Villanueva, Vicente
Meeting Abstract. 2021
Effectiveness, safety and tolerability of perampanel by age group when used to treat people with focal and generalized epilepsy in clinical practice: The PERMIT Extension study.
Wheless J; (...); Villanueva V
Article. 10.1016/j.yebeh.2023.109369. 2023
Effectiveness, safety and tolerability of perampanel in adolescents with focal and generalised seizures: evidence from clinical practice
Gil, Francisco; (...); Villanueva, Vicente
Meeting Abstract. 2021
Efficacy and safety of stiripentol in the prevention and cessation of status epilepticus: A systematic review.
Specchio N; (...); Trinka E
Article. 10.1002/epi4.13036. 2024
Efficacy of add-on Cenobamate treatment in refractory epilepsy due to Rasmussen's encephalitis.
Schulze-Bonhage A; (...); Villanueva V
Article. 10.1002/epi4.13060. 2024
Efficacy of stiripentol in the management of status epilepticus: A systematic review
Auvin, S.; (...); Trinka, E.
Meeting Abstract. 2024
Efficacy, Safety and Tolerability of Soticlestat (TAK-935/OV935) as Adjunctive Therapy in Pediatric Patients with Dravet Syndrome and Lennox-Gastaut Syndrome (ELEKTRA)
Hahn, Cecil D.; (...); Dlugos, Dennis
Meeting Abstract. 2021
Global pooled analysis of perampanel in epilepsy patients treated in routine clinical practice: the PERMIT study
Villanueva, Vicente; (...); Trinka, Eugen
Meeting Abstract. 2021
Guidance on Dravet syndrome from infant to adult care: Road map for treatment planning in Europe.
Cardenal-Muñoz E; (...); Aibar JÁ
Article. 10.1002/epi4.12569. 2022
Identifying key unmet needs and value drivers in the treatment of focal-onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through Multi-Criteria Decision Analysis (MCDA).
Villanueva V; (...); Subías-Labazuy S
Article. 10.1016/j.yebeh.2021.108222. 2021
Impact of antiseizure medication with a very long half-life on long term video-EEG monitoring in focal epilepsy.
Hampel, Kevin G.; (...); Villanueva, Vicente
Article. 10.1016/j.seizure.2023.12.010. 2023
Impact of COVID-19 on Spanish patients with Dravet syndrome and their caregivers: consequences of lockdown
Munoz, EC; (...); Aibar JA
Article. 10.33588/rn.7302.2021006. 2021
Impact of Polytherapy on Memory Functioning in Patients With Drug-Resistant Epilepsy: The Role of Attention and Executive Functions.
Lozano-Garcia, Alejandro; (...); Gonzalez-Bono, Esperanza
Article. 10.1093/arclin/acad086. 2023
Initial monotherapy with eslicarbazepine acetate for the management of adult patients with focal epilepsy in clinical practice: a meta-analysis of observational studies.
Fernandez-Anaya, Silvia; (...); Sarasa, Pilar
Article. 10.1080/00207454.2021.1925667. 2021
Involvement of mental health professionals in the treatment of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND): results of a multinational European electronic survey
Waltereit, R; (...); Auvin, S
Article. 10.1186/s13023-021-01800-w. 2021
La reserva cognitiva como factor modulador del impacto de la cirugía sobre la memoria visual y la denominación en pacientes con epilepsia del lóbulo temporal.
Cano-Lopez, I; (...); Gonzalez-Bono, E
Article. 10.33588/rn.7308.2021109. 2021
Long-Term Efficacy and Safety From an Open-Label Extension of Adjunctive Cenobamate in Patients With Uncontrolled Focal Seizures.
Klein, Pavel; (...); Villanueva, Vicente
Article. 10.1212/WNL.0000000000200792. 2022
Long-Term Soticlestat Treatment in Patients with Developmental and/or Epileptic Encephalopathies in the ENDYMION Ongoing Open-Label Extension Study
Hahn, Cecil D.; (...); Dlugos, Dennis
Meeting Abstract. 2021
Long-term, quality of life in epilepsy inventory-31 (QOLIE-31) improvements in adults with focal onset seizures treated with XEN1101 in an ongoing, open-
Brandt, C.; (...); Beatch, G. N.
Meeting Abstract. 2024
Management of patients with Dravet syndrome in real-world clinical practice across five countries in Europe: Impact of treatment-related burden on health outcomes
Ross, E.; (...); Andrews, J. S.
Meeting Abstract. 2024
New therapeutic approach in Dravet syndrome and Lennox-Gastaut syndrome with cannabidiol.
Villanueva V; (...); López-González FJ
Review. 10.33588/rn.72S01.2021017. 2021
Number needed to treat and associated cost analysis of cenobamate versus third-generation anti-seizure medications for the treatment of focal-onset seizures in patients with drug-resistant epilepsy in Spain.
Villanueva, Vicente; (...); Gil, Alicia
Article. 10.1016/j.yebeh.2022.109054. 2023
Patient profile, management, and quality of life associated with Dravet syndrome: a cross-sectional, multicentre study of 80 patients in Spain.
Gil-Nagel, Antonio, Sanchez-Carpintero, Rocio, Villanueva, Vicente
Article. 10.1038/s41598-023-30273-z. 2023
Perampanel as Early Add on Therapy for Epilepsy Patients with Focal -Onset an Generalized-Onset Seizures Treated in Clinical Practice(p1-1.Virtua)
Santamarina, Estevo; (...); Villanueva, Vicente
Meeting Abstract. 2022
Perampanel as Early Add on Therapy for Epilepsy Patients with Focal -Onset and Generalized-Onset Seizures Treated in Clinical Practice(p1-1.Virtual)
Santamarina, Estevo; (...); Villanueva, Vicente
Meeting Abstract. 2022
Perampanel as early add-on therapy for epilepsy patients with focal and generalised seizures treated in clinical practice
Santamarina Perez, Estevo; (...); Villanueva, Vicente
Meeting Abstract. 2021
Perampanel as Early Add-on Therapy for Epilepsy Patients with Focal and Generalized Seizures Treated in Clinical Practice
Santamarina, Estevo; (...); Villanueva, Vicente
Meeting Abstract. 2021
Perampanel for the treatment of Asian people with epilepsy: Real-world evidence from the PERMIT extension study.
Wu, Tony; (...); Villanueva, Vicente
Article. 10.1016/j.jns.2024.123173. 2024
Perampanel for the treatment of epilepsy with genetic aetiology: Real-world evidence from the PERMIT Extension study.
Delanty N; (...); Villanueva V
Article. 10.1016/j.eplepsyres.2024.107339. 2024
Perampanel for the treatment of focal and generalised seizures in patients with epilepsy with tumour aetiology: evidence from clinical practice
Coppola, Antonietta; (...); Villanueva, Vicente
Meeting Abstract. 2021
Perampanel for the treatment of patients with myoclonic seizures in clinical practice: Evidence from the PERMIT study
D'Souza, Wendyl; (...); Villanueva, Vicente
Article. 10.1016/j.seizure.2022.06.008. 2022
Perampanel for the Treatment of People with Idiopathic Generalized Epilepsy in Clinical Practice.
Trinka E; (...); Villanueva V
Article. 10.1111/epi.17631. 2023
Perampanel for treatment of epilepsy with tumour, vascular or traumatic brain injury aetiology: Evidence from the PERMIT extension study
Strzelczyk, A.; (...); Villanueva, V.
Meeting Abstract. 2024
Perampanel for treatment of focal and generalized epilepsy in everyday clinical practice: Evidence from permit extension
Trinka, Eugen; (...); Villanueva, Vicente
Meeting Abstract. 10.1016/j.jns.2023.121561. 2023
Perampanel for Treatment of People with a Range of Epilepsy Aetiologies in Clinical Practice: Evidence from the PERMIT Extension Study.
Strzelczyk, Adam; (...); Villanueva, Vicente
Article. 10.1007/s40120-024-00618-5. 2024
Perampanel in adult epilepsy patients treated in everyday clinical practice: results from an interim pooled analysis of real-world studies
Strzelczyk, Adam; (...); Villanueva, Vicente
Meeting Abstract. 2021
Perampanel Monotherapy for Focal and Generalized Epilepsy in Clinical Practice
Chinvarun, Yotin; (...); Villanueva, Vicente
Article. 10.1155/2023/2852853. 2023
Perampanel monotherapy in epilepsy patients with focal and generalised seizures: real-world experience
Alsaadi, Taoufik; (...); Villanueva, Vicente
Meeting Abstract. 2021
Perampanel outcomes at different stages of treatment in people with focal and generalized epilepsy treated in clinical practice: Evidence from the PERMIT study.
Liguori, Claudio; (...); Villanueva, Vicente
Article. 10.3389/fneur.2023.1120150. 2023
PERMIT study: a global pooled analysis study of the effectiveness and tolerability of perampanel in routine clinical practice
Villanueva, Vicente; (...); Trinka, Eugen
Article. 10.1007/s00415-021-10751-y. 2021
Predictors of seizure freedom, response and retention after 12 months of treatment with eslicarbazepine acetate: A post-hoc analysis of the Euro-Esli study
Sales, F; (...); Villanueva, V
Article. 10.1016/j.eplepsyres.2021.106653. 2021
Presurgical Use of Cenobamate for Adult and Pediatric Patients Referred for Epilepsy Surgery: Expert Panel Recommendations.
Laxer KD; (...); Villanueva V
Article. 10.1007/s40120-024-00651-4. 2024
Prognostic value of the 5-SENSE Score to predict focality of the seizure-onset zone as assessed by stereoelectroencephalography: a prospective international multicentre validation study.
Astner-Rohracher, Alexandra; (...); Frauscher, Birgit
Article. 10.1136/bmjno-2024-000765. 2024
Proposed Recommendations for the Management of Depression in Adults with Epilepsy: An Expert Consensus.
Villanueva, Vicente; (...); Bobes, Julio
Article. 10.1007/s40120-023-00437-0. 2023
Prospective study of cenobamate on cognition, affectivity and quality of life in focal epilepsy.
Catalan-Aguilar, Judit; (...); Villanueva, Vicente
Article. 10.1002/epi4.12857. 2023
Real-life evidence about the use of intravenous brivaracetam in urgent seizures: The BRIV-IV study.
Villanueva V; (...); Escalza I
Article. 10.1016/j.yebeh.2023.109384. 2023
Real-world clinical burden of non-seizure symptoms among patients with dravet syndrome or Lennox- Gastaut syndrome in Europe: Results from a global multinational survey
Berthoz, F. Truong; (...); Andrews, J. S.
Meeting Abstract. 2024
Real-World Experience of Perampanel Monotherapy in Epilepsy Patients with Focal-Onset and Generalized-Onset Seizures
Alsaadi, Taoufik; (...); Villanueva, Vicente
Meeting Abstract. 2022
Real-world experience of treating patients aged <12 years with perampanel
Auvin, Stephane; (...); Villanueva, Vicente
Meeting Abstract. 2021
Real-world safety and effectiveness of cenobamate in patients with focal onset seizures: outcomes from an Expanded Access Program.
Villanueva, Vicente; (...); Rodriguez-Uranga, Juan J.
Article. 10.1002/epi4.12757. 2023
Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome.
Nabbout, Rima; (...); Cross, J. Helen
Article. 10.1016/j.seizure.2023.05.003. 2023
Spanish consensus on the management of concomitant antiseizure medications when using cenobamate in adults with drug-resistant focal seizures.
Carreño M; (...); Villanueva V
Article. 10.1002/epi4.12936. 2024
Stereoencephalography-guided thermocoagulation: Experience in our centre
De Castro Garcia, A. Celdran; (...); Villanueva, V.
Meeting Abstract. 2024
Stress phenotypes in epilepsy: impact on cognitive functioning and quality of life.
Catalán-Aguilar J; (...); Cano-López I
Article. 10.3389/fpsyg.2023.1100101. 2023
Sustained =90% response and seizure freedom in patients with focal-onset seizures treated with cenobamate
Alvarez-Baron, E., Thangavelu, K., Villanueva, V.
Meeting Abstract. 2023
The Charlotte Project: Recommendations for patient-reported outcomes and clinical parameters in Dravet syndrome through a qualitative and Delphi consensus study.
Aledo-Serrano Á; (...); Sánchez-Carpintero R
Article. 10.3389/fneur.2022.975034. 2022
The relationship between memory and quality of life is mediated by trait anxiety in patients with temporal lobe epilepsy.
Cano-Lopez, Irene; (...); Gonzalez-Bono, Esperanza
Article. 10.1007/s11136-022-03306-9. 2022
The significance of very long half-life in the context of antiseizure medication withdrawal during long-term video-EEG monitoring.
Hampel, Kevin Gil; (...); Villanueva, Vicente
Letter. 10.1016/j.seizure.2024.01.006. 2024
Therapeutic strategies during cenobamate treatment initiation: Delphi panel recommendations
Steinhoff, Bernhard J.; (...); Villanueva, Vicente
Review. 10.1177/17562864241256733. 2024
Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials
Cohen, JM; (...); Zuberi, SM
Article. 10.1111/epi.16974. 2021
Treatment patterns and disease burden among patients with Lennox- Gastaut syndrome in Europe: A real-world survey
Benitez, A.; (...); Andrews, J. S.
Meeting Abstract. 2024
Use of Stiripentol in Patients with Dravet Syndrome: Common Practice Among Experts in Spain.
Garcia-Penas, Juan Jose; (...); Sanchez-Carpintero, Rocio
Article. 10.1007/s40120-024-00677-8. 2024
What do 90-99% responder rates mean in patients treated with cenobamate: results from an open label extension study
Serratosa, J.; (...); Villanueva, V.
Meeting Abstract. 2023
What do 90-99% responder rates mean in patients treated with cenobamate: results from the open label extension (OLE) of study C017?
Serratosa, J. M.; (...); Villanueva, V.
Meeting Abstract. 2023